Skip to content
TrialScanner

NCT03927261

PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

Phase 1Active, not recruitingPGENLead

Registry record

Lead sponsor
Precigen, Inc
Conditions
Acute Myeloid Leukemia; Myelodysplastic Syndromes
Primary completion
Aug 1, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03927261 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03927261: PRGN-3006 Adoptive Cellular... | TrialScanner